ArticleRMD open2021
Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis.
Article in RMD open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Gut microbiota dysbiosis in ankylosing spondylitis: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2024Pooled it
- Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.Gut microbes · 2023Pooled it
- Microbiome-metabolome generated bile acids gatekeep infliximab efficacy in Crohn's disease by licensing M1 suppression and Treg dominance.Journal of advanced research · 2026Observational
- Gut microbiota and ankylosing spondylitis: mechanisms, functional pathways, and research trends.Frontiers in microbiology · 2026Article
- Gut microbiota as a potential predictor of therapeutic response in adults with Crohn's disease: A systematic review.World journal of gastrointestinal pathophysiology · 2025Article
- Causal Relationship Between Gut Microbiota and Benign Prostatic Hyperplasia: A Two-Sample Mendelian Randomization Analyses, 16S rRNA Sequencing and Clinical Retrospective Study.Food science & nutrition · 2025Article
- Microbial threads in the tapestry of rheumatoid arthritis.The Journal of clinical investigation · 2025Review
- Interplay of Gut Microbiota, Biologic Agents, and Postoperative Anastomotic Leakage in Inflammatory Bowel Disease: A Narrative Review.International journal of molecular sciences · 2025Review
- Fecal microbiota and genetics in pediatric-onset orofacial granulomatosis and Crohn´s disease.Scientific reports · 2025Article
- Dysbiosis in Inflammatory Bowel Disease and Spondyloarthritis: Still a Long Way to Go?Journal of clinical medicine · 2024Review
- The effect of anti-TNF drugs on the intestinal microbiota in patients with spondyloarthritis, rheumatoid arthritis, and inflammatory bowel diseases.Rheumatology and immunology research · 2024Review
- Influence of TNF-α Inhibitors on Gut Microbiota and Immune Modulation in Treating Ankylosing Spondylitis: Insights into Therapeutic Mechanisms and Clinical Implications.Journal of inflammation research · 2024Article
- Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.Microbiome research reports · 2023Article
- The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors.Biomedicines · 2023Review
- Association between gut microbiota and benign prostatic hyperplasia: a two-sample mendelian randomization study.Frontiers in cellular and infection microbiology · 2023Article
- Identification of gut dysbiosis in axial spondyloarthritis patients and improvement of experimental ankylosing spondyloarthritis by microbiome-derived butyrate with immune-modulating function.Frontiers in immunology · 2023Article
- Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease.Frontiers in microbiology · 2023Review
- Article
- The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review.Genes · 2022Review
- Role of the microbiome and its metabolites in ankylosing spondylitis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe close relationship between joints and gut inflammation has long been known and several data suggest that dysbiosis could link spondyloarthritis (SpA) to inflammatory bowel diseases (IBD). The introduction of biological drugs, in particular tumour necrosis factor inhibitors (TNFi), revolutionised the management of both these diseases. While the impact of conventional drugs on gut microbiota is well known, poor data are available about TNFi.
aimTo investigate the impact of TNFi on gut microbiota.
methodsWe evaluated 20 patients affected by enteropathic arthritis, naïve for biological drugs, treated with TNFi at baseline and after 6 months of therapy. All patients followed a Mediterranean diet. Patients performed self-sampling of a faecal sample at baseline and after 6 months of therapy. NGS-based ITS and 16S rRNA gene sequencing was performed, followed by the taxonomic bioinformatics analysis.
resultsAfter 6 months of therapy, we detected a remarkable increase in Lachnospiraceae family (Δ +10.3, p=0.04) and Coprococcus genus (Δ +2.8, p=0.003). We also noted a decreasing trend in Proteobacteria (Δ -8.0, p=0.095) and Gammaproteobacteria (Δ -9, p=0.093) and an increasing trend in Clostridia (Δ +8.2, p=0.083). We did not find differences between TNFi responders (SpA improvement or IBD remission achieved) and non-responders in terms of alpha and beta diversity.
conclusionsOur findings are consistent with the hypothesis that TNFi therapy tends to restore the intestinal eubiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.